Eltrombopag (EPAG) Treatment Improved Platelet Counts in Patients with Persistent or Chronic Immune Thrombocytopenia during a 2-Year, Phase IV, Open-Label Study

Background: null ITP, characterized by isolated platelet reduction, is classified as persistent within 3- et al. Acta Haematol null 2017;137:66-72) was performed. null null Aims: null To evaluate the effects of EPAG on platelet counts, and long-term safety, during 2 yrs9 treatment, in persistent or cITP pts. null null Methods null : null Adults ≥18 yrs old diagnosed with persistent ITP (3- null null Results: null At BL, 37/162 (23%; mean ± SD...